ANI Pharmaceuticals will present at three upcoming investor conferences in March 2026, accessible via webcast.
Quiver AI Summary
ANI Pharmaceuticals, Inc. announced that CEO Nikhil Lalwani and the executive team will present at several upcoming investor conferences, including the Raymond James 47th Annual Institutional Investors Conference on March 3, the Leerink Partners Global Healthcare Conference on March 10, and the Barclays 28th Annual Global Healthcare Conference on March 11. Live and archived webcasts of these presentations will be available on the company's website for 90 days. ANI Pharmaceuticals specializes in developing and commercializing innovative therapeutics, focusing on areas such as rare diseases, generics, and branded products.
Potential Positives
- ANI Pharmaceuticals' participation in multiple reputable investor conferences highlights the company's commitment to transparency and engagement with investors, potentially enhancing investor confidence.
- The announcement emphasizes ANI Pharmaceuticals' diverse focus across various therapeutic areas, which may attract a broader range of investors interested in the biopharmaceutical sector.
- The accessibility of live and archived webcasts demonstrates ANI Pharmaceuticals' efforts to provide stakeholders with updated information and insights into the company's strategies and developments.
Potential Negatives
- None
FAQ
What investor conferences will ANI Pharmaceuticals participate in?
ANI Pharmaceuticals will present at the Raymond James, Leerink Partners, and Barclays healthcare conferences in March 2026.
Who will represent ANI Pharmaceuticals at the conferences?
Nikhil Lalwani, the President and CEO, along with the executive leadership team, will represent ANI Pharmaceuticals.
How can I access the conference webcasts?
The live and archived webcasts can be accessed on ANI Pharmaceuticals' website under the Investors section.
How long will the webcasts be available for replay?
The archived webcasts will be available for replay for 90 days after each conference.
What is ANI Pharmaceuticals known for?
ANI Pharmaceuticals is known for developing and commercializing innovative therapeutics in various medical fields, including rare diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ANIP Insider Trading Activity
$ANIP insiders have traded $ANIP stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.
Here’s a breakdown of recent trading of $ANIP stock by insiders over the last 6 months:
- CHAD GASSERT (SVP - CORP. DEV. & STRATEGY) has made 0 purchases and 2 sales selling 14,736 shares for an estimated $1,312,434.
- CHRISTOPHER MUTZ (HEAD OF RARE DISEASE) has made 0 purchases and 2 sales selling 12,355 shares for an estimated $953,600.
- PATRICK D WALSH sold 8,643 shares for an estimated $750,903
- ANTONIO R PERA sold 7,292 shares for an estimated $692,302
- KRISTA DAVIS (SVP, CHIEF HR OFFICER) has made 0 purchases and 4 sales selling 6,436 shares for an estimated $528,188.
- MEREDITH COOK (SR. VP, GENERAL COUNSEL & SEC.) has made 0 purchases and 6 sales selling 2,600 shares for an estimated $223,805.
- RENEE P TANNENBAUM sold 1,800 shares for an estimated $146,070
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ANIP Revenue
$ANIP had revenues of $227.8M in Q3 2025. This is an increase of 53.58% from the same period in the prior year.
You can track ANIP financials on Quiver Quantitative's ANIP stock page.
$ANIP Hedge Fund Activity
We have seen 158 institutional investors add shares of $ANIP stock to their portfolio, and 124 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC removed 559,670 shares (-96.5%) from their portfolio in Q4 2025, for an estimated $44,180,349
- MILLENNIUM MANAGEMENT LLC added 474,420 shares (+727.1%) to their portfolio in Q4 2025, for an estimated $37,450,714
- UBS GROUP AG removed 439,095 shares (-74.4%) from their portfolio in Q4 2025, for an estimated $34,662,159
- RUBRIC CAPITAL MANAGEMENT LP removed 343,414 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $27,109,101
- MACQUARIE GROUP LTD removed 291,129 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $22,981,723
- POINT72 ASSET MANAGEMENT, L.P. removed 277,881 shares (-69.6%) from their portfolio in Q4 2025, for an estimated $21,935,926
- DIVISADERO STREET CAPITAL MANAGEMENT, LP removed 234,219 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $18,489,247
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ANIP Analyst Ratings
Wall Street analysts have issued reports on $ANIP in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 11/10/2025
- JP Morgan issued a "Overweight" rating on 09/24/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/17/2025
To track analyst ratings and price targets for $ANIP, check out Quiver Quantitative's $ANIP forecast page.
$ANIP Price Targets
Multiple analysts have issued price targets for $ANIP recently. We have seen 5 analysts offer price targets for $ANIP in the last 6 months, with a median target of $115.0.
Here are some recent targets:
- Vamil Divan from Guggenheim set a target price of $124.0 on 01/16/2026
- Glen Santangelo from Barclays set a target price of $100.0 on 12/09/2025
- Gregory Fraser from Truist Securities set a target price of $90.0 on 10/09/2025
- Ekaterina Knyazkova from JP Morgan set a target price of $115.0 on 09/24/2025
- Brandon Folkes from HC Wainwright & Co. set a target price of $121.0 on 09/17/2025
Full Release
PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company’s executive leadership team, will present at the following investor conferences:
-
Raymond James & Associates’ 47th Annual Institutional Investors Conference on Tuesday, March 3, 2026, at 7:30am ET
-
Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026, at 3:00pm ET
-
Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026, at 3:00pm ET
The live and archived webcasts will be accessible from the Company’s website at www.anipharmaceuticals.com , under the Investors section under Events and Presentations. The replays of the webcasts will be accessible for 90 days.
About ANI
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit
www.anipharmaceuticals.com
.
Investor Relations:
Courtney Mogerley, Argot Partners
T: 646-368-8014
E:
[email protected]
